Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,712.99
(
0.28%
)
News Focus
News Focus
Post# of 257266
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 168950

Monday, 11/18/2013 2:50:37 PM

Monday, November 18, 2013 2:50:37 PM

Post# of 257266
EU brand name for GILD’s standalone elvitegravir is Vitekta (a little awkward to pronounce), which is now formally approved for marketing in the EU:

http://www.biospace.com/News/european-commission-ec-approves-gilead-sciences/316028/

Standalone Vitekta figures to be a minor product because most use of the drug will be in the form of Stribild, the combination of elvitegravir and Truvada.

In the US, standalone elvitegravir received a CRL in Apr 2013 (#msg-87357861) even though Stribild was approved in Aug 2012.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today